Medimmune Limited

Viela Bio, Inc.

Boston Pharmaceuticals, Inc.

Stacey Drabic

Ronald Herbst

Manuel Baca

Changshou Gao

Partha S Chowdhury

Melissa Marie Damschroder

Anthony Coyle

Scott A Hammond

Claire Louise Dobson

Xiaodong Xiao

Reena Varkey

Godfrey Rainey

Darren Schofield

Michelle Morrow

Ping Tsui

Srinath Kasturirangan

Qun Du

Yariv Mazor

Thomas Thisted

Vaheh Oganesyan

Michael Oberst

Brian Lobo

Prakash Manikwar

Simon Dovedi

Gianluca Carlesso

Catherine Ettinger

Jonathan Seaman

Laura Carter

Brian Michael Naiman

Kristen Pollizzi

Luba Grinberg

Shabazz Novarra

David Kenneth Spencer

Jodi Karnell

Manual Baca

Peter Emtage

Partha Chowdhury

Melissa Damschroder

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

Bispecific binding proteins and uses thereof

The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.

Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer

This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.

Antibodies specific for IL-21 and uses thereof

Nucleic acids encoding a Tn3 scaffold comprising a CD40L-specific monomer subunit

Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-L1 antibody).

CD40L-Fc fusion polypeptides and methods of use thereof

CD40L-specific TN3-derived scaffolds and methods of use thereof

Growing community of inventors

Gaithersburg, MD, United States of America

Stacey Drabic